Jacqueline E. Shea, CEO, announced continued progress on strategic priorities, with a primary focus on submitting the BLA for INO-3107 in the second half of the year and targeting file acceptance by ...

Complete submission of the Biologics License Application (BLA) remains on track for 2H25 with the goal of file acceptance by U.S. Food and Drug Administration (FDA) by end of 2025 PLYMOUTH MEETING, Pa ...